About: Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice
Creator	Deng, Yong-Qiang Qin, Cheng-Feng Cheng, Genhong Li, Xiao-Feng Nielsen-Saines, Karin Tian, Min Xu, Zhiheng Aliyari, Roghiyh Ji, Xue Li, Chunfeng Quanquin, Natalie Yuan, Ling Zhu, Xingliang Zuo, Xiangyang Frank, Xiao-Feng Jung, Jae Khan, Shabbir Qin,
Source	Elsevier; Medline; PMC
abstract	Zika virus (ZIKV) has become a global public health emergency due to its rapidly expanding range and its ability to cause severe congenital defects such as microcephaly. However, there are no FDA-approved therapies or vaccines against ZIKV infection. Through our screening of viral entry inhibitors, we found that chloroquine (CQ), a commonly used antimalarial and a FDA-approved drug that has also been repurposed against other pathogens, could significantly inhibit ZIKV infection in vitro, by blocking virus internalization. We also demonstrated that CQ attenuates ZIKV-associated morbidity and mortality in mice. Finally, we proved that CQ protects fetal mice from microcephaly caused by ZIKV infection. Our methodology of focusing on previously identified antivirals in screens for effectiveness against ZIKV proved to be a rapid and efficient means of discovering new ZIKV therapeutics. Selecting drugs that were previously FDA-approved, such as CQ, also improves the likelihood that they may more quickly reach stages of clinical testing and use by the public.
has issue date	2017-09-28(xsd:dateTime)
bibo:doi	10.1016/j.ebiom.2017.09.034
bibo:pmid	29033372
has license	cc-by-nc-nd
sha1sum (hex)	c7a3699cbb6e8ea60edabb60c0407883e6ed33f2
schema:url	https://doi.org/10.1016/j.ebiom.2017.09.034
resource representing a document's title	Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice
has PubMed Central identifier	PMC5652284
has PubMed identifier	29033372
schema:publication	EBioMedicine
resource representing a document's body	covid:c7a3699cbb6e8ea60edabb60c0407883e6ed33f2#body_text
is schema:about of	named entity 'discovering' named entity 'testing' named entity 'chloroquine' named entity 'expanding' named entity 'range' named entity 'ZIKV INFECTION' named entity 'PREVENTS' covid:arg/c7a3699cbb6e8ea60edabb60c0407883e6ed33f2 named entity 'APPROVED' named entity 'ASSOCIATED' named entity 'ORG' named entity 'OUR' named entity 'DEMONSTRATED' named entity 'FETAL' named entity 'LIKELIHOOD' named entity 'RAPIDLY' named entity 'CONGENITAL DEFECTS' named entity 'DRUGS' named entity 'ENTRY INHIBITORS' named entity 'MICROCEPHALY' named entity 'APPROVED' named entity 'FDA' named entity 'PATHOGENS' named entity 'THERAPIES' named entity 'NC-' named entity 'CONGENITAL MICROCEPHALY' named entity 'MICE' named entity 'ZIKA VIRUS INFECTION' named entity 'DRUG' named entity 'LICENSE' named entity 'CHLOROQUINE' named entity 'FDA' named entity 'SEVERE' named entity 'DRUG' named entity 'ITS' named entity 'EXPANDING' named entity 'VACCINES' named entity 'DUE TO' named entity 'REACH' named entity 'ASSOCIATED' named entity 'CHLOROQUINE' named entity 'RAPID' named entity 'BLOCKING' named entity 'STAGES' named entity 'USE' named entity 'CLINICAL TESTING' named entity 'IN VITRO' named entity 'CAUSE' named entity 'MICE' named entity 'ANTIMALARIAL' named entity 'VIRAL ENTRY' named entity 'ANTIVIRALS' named entity 'ZIKA VIRUS' named entity 'SCREENING' named entity 'IMPROVES' named entity 'SELECTING' named entity 'RANGE' named entity 'MEANS' named entity 'GLOBAL' named entity 'USED' named entity 'ITS' named entity 'FOUND' named entity 'PREVIOUSLY' named entity 'EFFECTIVENESS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software